---
title: "SELLAS Life Sciences Group, Inc. (SLS.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/SLS.US.md"
symbol: "SLS.US"
name: "SELLAS Life Sciences Group, Inc."
industry: "Biotechnology"
datetime: "2026-05-21T15:56:35.205Z"
locales:
  - [en](https://longbridge.com/en/quote/SLS.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SLS.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SLS.US.md)
---

# SELLAS Life Sciences Group, Inc. (SLS.US)

## Company Overview

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [ellaslifesciences.com](https://ellaslifesciences.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -56.65 | 539 | - | - | - |
| PB | 15.54 | 404 | 13.40 | 7.73 | 6.15 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-13T04:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 50% |
| Overweight | 1 | 50% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 7.99 |
| Highest Target | 10.00 |
| Lowest Target | 10.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/SLS.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/SLS.US/norm.md)
- [Related News](https://longbridge.com/en/quote/SLS.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/SLS.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**